Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales, Adoption by Application & Technology The global precision medicine market will witness a robust CAGR of 11.52%, valued at $72.73 Bn in 2022, and destined to appreciate and reach $175.6 billion by 2030, confirms Strategic Market Research. North America dominates the precision medicine market by a revenue share of 40% due to the rising prevalence of chronic diseases, massive expenditure on R&D, and growth in demand for precision medicine. Precision medicine is a cutting-edge strategy for customizing disease prevention and treatment. Considering a patient's unique genetic & molecular makeup, environment, and lifestyle enables medical professionals & researchers to predict which suitable treatment is of utmost benefit for a given patient. The government is setting the standard for precision medicine, diving deep into the biology of chronic diseases using multi-omics, cutting-edge technologies, imaging, artificial intelligence, and machine learning. The goal is to create and validate new treatments for earlier diagnosis and intervention, stop disease progression, achieve remission, and improve patient outcomes and future health. Precision medicine offers advantages like predicting susceptibility to disease, preventing disease progression, prescribing more effective drugs, and reducing clinical trial time, cost, and failure rate. Precision medicine is particularly related to drug discovery and development. The industry has turned very attractive in the past few years, and there are several reasons for this. The spending on R&D in the healthcare industry has doubled in the last seven years, and better technologies and drug development mechanisms are in place. As the adoption of machine learning algorithms and A.I. in the field of drug development continues to rise, precision medicine solutions will gain more adoption and demand. Companies involved in drug development and discovery must understand that A.I.-based clinical decision support is the future. Hence, investing in advanced solutions to generate better insights and logical reasoning based on data patterns and computational techniques is the key to making a mark in precision medicine and personalized drug development. It should be noted that conventional drug portfolios and drug development techniques are witnessing rapid change. Companies are moving from one-size-fits-all to a more customized approach in the field of drug discovery and medication. In the present scenario, there are multiple drugs being developed in the same category of disease profiles based on cluster analysis of patient groups and various other patterns. This approach brings in the idea of customized medicine based on the patient-specific use case in various diseases like cancer, neurological diseases, respiratory problems, and others. Market Dynamics – Rapid increase in the prevalence of cancer, Increased Medical Tourism, and growing technological advancements in healthcare. The rising prevalence of cancer, the expanding number of treatment candidates in clinical trials, and the increase in the number of genetic diseases are significant drivers for the market's growth. As per the National Cancer Institute, the rate of fresh cases of cancer is 442.4 per 100,000 women and men per year. The death rate due to cancer is 158.3 per 100,000 women and men per year. An estimated 16,850 children and adolescents aged b/w 0 to 19 are diagnosed with cancer, and 1,730 die from the disease. Precision medicine prevents drug reactions and increases the number of treatment options, driving the medical tourism industry in European countries. For example, the government of the United Kingdom set up 3 advanced therapy treatment centers for the advancement of precision medicine and gene therapies by investing around $70 million in the Industry strategy challenge fund to enhance healthcare infrastructure. Technological advancements in the areas like genomic sequencing, molecular diagnostics & data analytics have fuelled the growth of precision medicine. Next-generation sequencing (NGS) technologies have transformed genomic research & made it possible to sequence entire genomes, identify genetic alterations, and detect biomarkers associated with specific illnesses. Additionally, advancements in data analytics and machine learning algorithms enable the integration of diverse datasets to derive actionable insights for personalized treatment decisions. AI-enabled personalized medicine will give individuals access to their unique genome, allowing them to receive special treatments and protocols to mitigate the consequences of life-altering diseases. Restraints – Lack of skilled professionals and high cost associated with precision medicine The presence of high-cost associated with precision medicine and the lack of skilled labor in developing and underdeveloped countries are impeding the market's growth. The outbreak of COVID-19 and the implementation of stringent regulations are further restraining the market's growth. Opportunities – Increase in the rate of R&D activities as well as adoption of advanced technologies The growing number of emerging markets, increase in R&D activities, and government initiatives such as the Swiss Personalized Health Network is augmenting the market growth. This health network is to promote the development of personalized medicine and health in Switzerland, providing beneficial opportunities for market growth. Sanford Health invested USD 50 million in august 2020 to help Veteran Affairs (V.A.) physicians use precision medicine to better match medication to individual cancer survivors. The increase in the focus of manufacturers on adoption of advanced technologies like Next Generation Sequencing (NGS) Test, application of molecular diagnostics, Cancer genome sequencing, Evidence-based medicine, Molecular medicine, CRISPR, Biomarkers, Biobanking, and Genetic sequencing will further provide beneficial opportunities for the personalized medicine market growth during the forecasted period. Global Precision Medicine Market:- Analysis of different Segmentations: The worldwide Precision Medicine Market segmentation is based on Technology, Application, End User, Sequencing Technology, Product, Route of Administration, Drugs, Region. Based on Technology Big Data Analytics Gene Sequencing Bioinformatics Companion Diagnostics Drug Discovery Other Technologies Based on Application Oncology Respiratory CNS Immunology Other Applications Based on End-User Healthcare Providers Pharmaceutical and Biotechnology Companies Research Centers and Academic Institutes Other End Users (non-profit organizations) By Sequencing Technology Sequencing by Synthesis Ion Semiconductor Sequencing Sequencing by Ligation Pyrosequencing Single Molecule Real Time Sequencing Chain Termination Sequencing Nanopore Sequencing By Product Consumables Instruments Services By Route of Administration Oral Injectable By Drugs Alectinib Osimertinib Mepolizumab Aripiprazole Lauroxil Others Regional Coverage Analysis North America • U.S. • Mexico • Canada • Rest of North America Europe • France • Germany • U.K • Italy • Spain • Rest of Europe Asia Pacific • India • China • South Korea • Japan • Australia • Rest of APAC LAMEA • Brazil • Saudi Arabia • Uruguay • Argentina • Rest of LAMEA Based on Technology, the drug discovery segment dominated the overall market with a share of 21.5 percent during the forecasted period. The factors such as an increase in research and development initiatives by both public and private companies to develop novel drugs, advances in pharmacogenomics, and an increase in demand for developing precision medicine are driving the segment growth. According to the article published by the National Library of Medicine with the title," The Influence of Industrial and Academic Collaboration on Drug Discovery and Development," the success rates of drug discovery and development is about 75% in phase I, 50% in phase II, 59% in phase III, and 88% at the new drug application phase. Based on Applications, the oncology segment dominated the market with a share of 40 percent and a CAGR of 10.8 percent in 2020. It is mainly due to the rising prevalence of cancer cases globally. As per the survey conducted by Breastcancer.org, in July 2020, in 534 patients, 31.7% of the individuals diagnosed with breast-cancer were reported with a major delay in care. Out of these people, nearly 22% reported a delay in screening, and 9.3% reported a delay in treatment due to the COVID-19 pandemic in the U.S. The wide applications of precision medicine in oncology research, the rise in funding in cancer research, and increased investments by government organizations in precision medicine software are propelling the overall growth of this segment. Based on End Users, the Pharmaceutical & Biotechnology Companies segment held the maximum share of 33 percent and a CAGR of 11 percent in 2020. The factors such as the usage of innovative technologies and the presence of major market players engaged in various investment programs are driving the segment's overall growth. The pharmaceutical industry and global health 2021 reported that biopharmaceutical companies spend USD 179 billion on R&D globally; compared with other high-technology industries. The annual R&D spending by the biopharmaceutical industry is 7.3 times greater than that of the aerospace and defense industries, 6.5 times more than that of the chemicals industry, and 1.5 times more than that of the software and computer services industry. Based on Regions, Based on region, North America dominates the precision medicine market with a revenue share of 40% and is estimated to spearhead the industry for the forecasted period. According to WHO, 41 million deaths are due to chronic diseases, and 38% are in the North American region. The precision medicine market in Europe is projected to register the CAGR of 8.95% during the forecast period. On the contrary, the European Union has commenced developing various policies which will witness precision medicine advancing healthcare in the European region. There has been a significant investment in genomics of around €3.2 billion channelized into innovation and research in precision medicine. APAC is going to witness a CAGR of 10.2% during the projected period and the market stood at $11.99 Billion in the year 2022. The reason for this remarkable growth is because of various programmes and initiatives. In Singapore multiple efforts are made to execute a National Precision Medicine Programme. The Lee Kong Chan School of Medicine which is a part of Nanyang Technological University has established and led a study called Health for Life in Singapore. Precision Medicine Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 65.22 Billion The revenue forecast in 2030 USD 174.6 Billion Growth rate 11.52% The base year for estimation 2020 Historical data 2017 - 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation Technology, Application, End User, Sequencing Technology, Product, Route of Administration, Drugs, Region. By Technology Bioinformatics, Big Data Analytics, Drug Discovery, Gene Sequencing, Companion Diagnostics By Application Respiratory, Oncology, Immunology, CNS By End-User Healthcare Providers, Research Centers and Academic Institutes, Pharmaceutical and Biotechnology Companies By Region North America, Europe, Asia Pacific and LAMEA Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Syapse, Inc., Foundation Medicine, 2bPrecise LLC, SOPHiA GENETICS SA, Fabric Genomics PierianDx, Inc., Human Longevity, Koninklijke Philips N.V. N-of-One, Translational Software, Inc., Sunquest Information Systems Inc., Gene42, Inc., LifeOmic Health, Tempus Labs, Inc., Flatiron Health, Inc., LLC, NantHealth, Inc., IBM Watson Group, etc, Abbott, AB-Biotics SA, GE Healthcare, LABORATORY CORPORATION OF AMERICA HOLDINGS, Biocrates Life Sciences, ABBOTT LABORATORIES, Glaxosmithkline Plc (GSK), Genelex, Johnson & Johnson, HealthCore, Inc., Dako A/S, Koninklijke Philips N.V. Global Precision Medicine Market: Competitive Landscape Analysis It provides information about the pivotal competitors prevailing in the market. The comparison is conducted based on key development strategies, market share, market ranking analysis, overall revenue generation, company overview, R&D investments, market initiatives, company financials, company weaknesses & strengths, production capacity, global presence, production facilities, sites, market potential, etc. The major competitors in the market are: Syapse, Inc. 2bPrecise LLC Gene42, Inc. Foundation Medicine, Inc. Fabric Genomics SOPHiA GENETICS SA PierianDx, Inc. Translational Software, Inc. N-of-One, Inc. Human Longevity, Inc. Sunquest Information LLC NantHealth, Inc. LifeOmic Health Tempus Labs, Inc. Flatiron Health, Inc. IBM Watson Group Koninklijke Philips N.V. Abbott AB-Biotics SA GE Healthcare LABORATORY CORPORATION OF AMERICA HOLDINGS Biocrates Life Sciences ABBOTT LABORATORIES Glaxosmithkline Plc (GSK) Genelex Johnson & Johnson HealthCore, Inc. Dako A/S Recent Developments On November 2022, MedStar Health partnered with Zephyr AI, Inc. announced to create AI-enabled precision medicine tools to improvise outcomes and results for chronic diseases, beginning with type 2 diabetes (T2D). A Zephyr AI product that performs predictive analytics will be enhanced by utilizing de-identified T2D datasets from MedStar Health and patient management know-how. The AI tool will assist in improving the opportunity for T2D interventions and reducing unfavorable outcomes like dialysis, chronic kidney disease, foot ulcers, and amputations. The partnership is an initiative to use AI and machine learning (ML) to assess the progression of chronic diseases and support chronic disease management. On May 2023, Google Cloud is focused on AI tools to provide precision medicine by collaborating with Pfizer and Colossal Biosciences. The multiomics suite is focused on interpreting and discovery of genomic data to help provide precision medicine. The target and lead identification suite offers AI based data sharing using Google Cloud to various healthcare organization. AI tools like AlphaFold2 and Vertex AI helps organizations to predict the results and optimise the accuracy of precision medicine. On May 2023, Closed Loop Medicine partnered with Pharmanovia to develop a software version of anti-hypertensive therapy. The Software-as-a-Medical device of Closed loop medicine incorporated with Anti-Hypertensive drug of Pharmanovia will optimise the dosage of the patient, improving the blood pressure control and significantly reducing the side effects. Frequently Asked Question About This Report What does precision mean in healthcare? In the healthcare industry, precision refers to an emerging and innovative approach to disease treatment and prevention that considers individual variability in genes and lifestyle for each individual. At what value of CAGR is the Precision Medicine Market expected to grow during the forecast period? Precision Medicine Market Share was USD 65.22 billion in 2020 & will reach USD 175.6 billion by 2030 with a CAGR of 11.5 percent. What will be the overall value of the Precision Medicine Market during the forecast period? Precision Medicine Market Value was USD 65.22 billion in 2021 and will reach USD 175.6 billion by 2030 with a CAGR of 11.5 percent. What is the largest market based on application? The Precision Medicine Oncology Market is the fastest-growing segment based on application. What is an example of precision medicine? Examples of precision medicine are Evidence-based medicine, Molecular medicine, and cancer genome sequencing. What is the future of precision medicine? The global precision medicine Software Market is predicted to reach USD 175.6 billion by 2030 with a CAGR of 11.5 percent. What is the value of precision medicine? The value of the worldwide Precision Medicine Market was USD 65.22billion in 2021 and will reach USD 175.6 billion by 2030. References: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447871/ https://www.cancer.gov/about-cancer/understanding/statistics https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match https://www.globenewswire.com/news-release/2020/08/21/2081816/0/en/RenalytixAI-to-Collaborate-with-AstraZeneca-to-Improve-Outcomes-for-Patients-with-Chronic-Disease.html https://pubmed.ncbi.nlm.nih.gov/30251934/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226120/ https://www.breastcancer.org/research-news/covid-19-delayed-screening-in-us https://www.ifpma.org/wp-content/uploads/2021/04/IFPMA-Facts-And-Figures-2021.pdf https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html https://www.oncodesign.com/cpt_ressource/sengine-precision-medicine-and-oncodesign-announce-collaboration-agreement-for-the-discovery-of-new-personalized-cancer-treatment-for-aggressive-and-untreatable-tumors/ https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-scorpion-therapeutics-enter-agreement-to-discover-develop-and-commercialise-novel-cancer-treatments-against-undruggable-targets.html https://www.epicsciences.com/press-releases/epic-sciences-enters-into-exclusive-licensing-agreement-and-collaboration-with-usc-michelson-center-to-advance-next-generation-liquid-biopsy-technology-for-precision-oncology/ https://www.diaceutics.com/articles/diaceutics-launches-worlds-first-diagnostic-network-for-precision-medicine-to-solve-global-cancer-testing-issues https://www.strategicmarketresearch.com/market-report/precision-medicine-market https://www.astrazeneca.com/r-d/precision-medicine.html https://www.jax.org/personalized-medicine/precision-medicine-and-you/what-is-precision-medicine https://www.ncbi.nlm.nih.gov/ https://emea.illumina.com/areas-of-interest/precision-health.html https://emea.illumina.com/areas-of-interest/precision-health/precision-genomics.html https://www.frontiersin.org/articles/10.3389/fphar.2021.720694/full https://www.forbes.com/sites/forbestechcouncil/2023/01/24/ais-biggest-promise-the-democratization-of-precision-medicine/ https://www.nature.com/articles/gim2016183 https://healthitanalytics.com/news/ 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key Material insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Precision Medicine Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Material Outlook 4.1 Market Snapshot 4.2 Precision Medicine Market 4.2.1 Market, 2020 – 2028 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, by region, 2021-2030 (USD Million) 4.4 Based on Technology Business Analysis 4.4.1 Market, Based on Technology, 2021-2030 (USD Million) 4.5 Based on Application Business Analysis 4.5.1 Market, Based on Application, 2021-2030 (USD Million) 4.6 Based on End-User Business Analysis 4.6.1 Market, Based on End-User, 2021-2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-User Analysis 5.11.1. Trends in End-User (2014-2020) 5.11.2. Trends in End-User (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: Based on Technology Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Big Data Analytics 7.3.1. Big Data Analytics, 2021-2030 (USD Million) 7.4. Bioinformatics 7.4.1. Bioinformatics Market, 2021-2030 (USD Million) 7.5. Gene Sequencing 7.5.1. Gene Sequencing Market, 2021-2030 (USD Million) 7.6. Drug Discovery 7.6.1. Drug Discovery Market, 2021-2030 (USD Million) 7.7. Companion Diagnostics 7.7.1. Companion Diagnostics Market, 2021-2030 (USD Million) 7.8. Other Technologies 7.8.1. Other Technologies Market, 2021-2030 (USD Million) 8. Market: Based on Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Oncology 8.3.1. Oncology Market, 2021-2030 (USD Million) 8.4. CNS 8.4.1. CNS Market, 2021-2030 (USD Million) 8.5. Immunology 8.5.1. Immunology Market, 2021-2030 (USD Million) 8.6. Respiratory 8.6.1. Respiratory Market, 2021-2030 (USD Million) 8.7. Other Applications 8.7.1. Other Applications Market, 2021-2030 (USD Million) 9. Market: Based on End-User Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Healthcare Providers 9.3.1. Healthcare Providers Market, 2021-2030 (USD Million) 9.4. Pharmaceutical and Biotechnology Companies 9.4.1. Pharmaceutical and Biotechnology Companies Market, 2021-2030 (USD Million) 9.5. Research Centers and Academic Institutes 9.5.1. Research Centers and Academic Institutes Market, 2021-2030 (USD Million) 9.6. Other End Users (non-profit organizations) 9.6.1. Other End Users (non-profit organizations) Market, 2021-2030 (USD Million) 10. Market: Regional Outlook 10.1 North America 10.1.1. North America Market, Based on Technology, 2021-2030 (USD Million) 10.1.2. North America Market, Based on Application, 2021-2030 (USD Million) 10.1.3. North America Market, Based on End-User, 2021-2030 (USD Million) 10.1.4. North America Market, by Country, 2021-2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. Market, Based on Technology, 2021-2030 (USD Million) 10.1.4.1.2. U.S. Market, Based on Application, 2021-2030 (USD Million) 10.1.4.1.3. U.S. Market, Based on End-User, 2021-2030 (USD Million) 10.1.4.2. Canada 10.1.4.2.1. Canada Market, Based on Technology, 2021-2030 (USD Million) 10.1.4.2.2. Canada Market, Based on Application, 2021-2030 (USD Million) 10.1.4.2.3. Canada Market, Based on End-User, 2021-2030 (USD Million) 10.2. Europe 10.2.1. Europe Market, Based on Technology, 2021-2030 (USD Million) 10.2.2. Europe Market, Based on Application, 2021-2030 (USD Million) 10.2.3. Europe Market, Based on End-User, 2021-2030 (USD Million) 10.2.4. Europe Market, by country, 2021-2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. Market, Based on Technology, 2021-2030 (USD Million) 10.2.4.1.2. U.K. Market, Based on Application, 2021-2030 (USD Million) 10.2.4.1.3. U.K. Market, Based on End-User, 2021-2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany Market, Based on Technology, 2021-2030 (USD Million) 10.2.4.2.2. Germany Market, Based on Application, 2021-2030 (USD Million) 10.2.4.2.3. Germany Market, Based on End-User, 2021-2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France Market, Based on Technology, 2021-2030 (USD Million) 10.2.4.3.2. France Market, Based on Application, 2021-2030 (USD Million) 10.2.4.3.3. France Market, Based on End-User, 2021-2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe Market, Based on Technology, 2021-2030 (USD Million) 10.2.4.4.2. Rest of Europe Market, Based on Application, 2021-2030 (USD Million) 10.2.4.4.3. Rest of Europe Market, Based on End-User, 2021-2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific Market, Based on Technology, 2021-2030 (USD Million) 10.3.2. Asia Pacific Market, Based on Application, 2021-2030 (USD Million) 10.3.3. Asia Pacific Market, Based on End-User, 2021-2030 (USD Million) 10.3.4. Asia Pacific Market, by country, 2021-2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China Market, Based on Technology, 2021-2030 (USD Million) 10.3.4.1.2. China Market, Based on Application, 2021-2030 (USD Million) 10.3.4.1.3. China Market, Based on End-User, 2021-2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India Market, Based on Technology, 2021-2030 (USD Million) 10.3.4.2.2. India Market, Based on Application, 2021-2030 (USD Million) 10.3.4.2.3. India Market, Based on End-User, 2021-2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan Market, Based on Technology, 2021-2030 (USD Million) 10.3.4.3.2. Japan Market, Based on Application, 2021-2030 (USD Million) 10.3.4.3.3. Japan Market, Based on End-User, 2021-2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea Market, Based on Technology, 2021-2030 (USD Million) 10.3.4.4.2. South Korea Market, Based on Application, 2021-2030 (USD Million) 10.3.4.4.3. South Korea Market, Based on End-User, 2021-2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC Market, Based on Technology, 2021-2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC Market, Based on Application, 2021-2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC Market, Based on End-User, 2021-2030 (USD Million) 10.4. Latin America 10.4.1. Latin America Market, Based on Technology, 2021-2030 (USD Million) 10.4.2. Latin America Market, Based on Application, 2021-2030 (USD Million) 10.4.3. Latin America Market, Based on End-User, 2021-2030 (USD Million) 10.4.4. Latin America Market, by country, 2021-2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil Market, Based on Technology, 2021-2030 (USD Million) 10.4.4.1.2. Brazil Market, Based on Application, 2021-2030 (USD Million) 10.4.4.1.3. Brazil Market, Based on End-User, 2021-2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico Market, Based on Technology, 2021-2030 (USD Million) 10.4.4.2.2. Mexico Market, Based on Application, 2021-2030 (USD Million) 10.4.4.2.3. Mexico Market, Based on End-User, 2021-2030 (USD Million) 10.4.4.3. Rest of Latin America 10.4.4.3.1. Rest of the Latin America Market, Based on Technology, 2021-2030 (USD Million) 10.4.4.3.2. Rest of the Latin America Market, Based on Application, 2021-2030 (USD Million) 10.4.4.3.3. Rest of the Latin America Market, Based on End-User, 2021-2030 (USD Million) 10.5. MEA 10.5.1. MEA Market, Based on Technology, 2021-2030 (USD Million) 10.5.2. MEA Market, Based on Application, 2021-2030 (USD Million) 10.5.3. MEA Market, Based on End-User, 2021-2030 (USD Million) 10.5.4. MEA Market, by Region, 2021-2030 (USD Million) 11. Competitive Landscape 11.1 SYAPSE, INC. 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. Product Portfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. 2bPrecise LLC 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. Gene42, Inc. 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. Foundation Medicine, Inc. 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. FABRIC GENOMICS 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. SOPHiA GENETICS SA 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. PIERIANDX, INC. 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Translational Software, Inc. 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. N-of-One, Inc. 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Human Longevity, Inc. 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. Sunquest Information 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. LLC 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. NantHealth, Inc 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. LifeOmic Health 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.15. Tempus Labs, Inc. 11.15.1. Company overview 11.15.2. Financial performance 11.15.3. Product Portfolio Analysis 11.15.4. Business Strategy & Recent Development 11.16. FLATIRON HEALTH, INC. 11.16.1. Company overview 11.16.2. Financial performance 11.16.3. Product Portfolio Analysis 11.16.4. Business Strategy & Recent Development 11.17. IBM Watson Group. 11.17.1. Company overview 11.17.2. Financial performance 11.17.3. Product Portfolio Analysis 11.17.4. Business Strategy & Recent Development 11.18. Koninklijke Philips N.V.. 11.18.1. Company overview 11.18.2. Financial performance 11.18.3. Product Portfolio Analysis 11.18.4. Business Strategy & Recent Development 11.19. Abbott 11.19.1. Company overview 11.19.2. Financial performance 11.19.3. Product Portfolio Analysis 11.19.4. Business Strategy & Recent Development 11.20. AB-Biotics SA 11.20.1. Company overview 11.20.2. Financial performance 11.20.3. Product Portfolio Analysis 11.20.4. Business Strategy & Recent Development 11.21. GE Healthcare 11.21.1. Company overview 11.21.2. Financial performance 11.21.3. Product Portfolio Analysis 11.21.4. Business Strategy & Recent Development 11.22. LABORATORY CORPORATION OF AMERICA HOLDINGS 11.22.1. Company overview 11.22.2. Financial performance 11.22.3. Product Portfolio Analysis 11.22.4. Business Strategy & Recent Development 11.23. Biocrates Life Sciences 11.23.1. Company overview 11.23.2. Financial performance 11.23.3. Product Portfolio Analysis 11.23.4. Business Strategy & Recent Development 11.24. ABBOTT LABORATORIES 11.24.1. Company overview 11.24.2. Financial performance 11.24.3. Product Portfolio Analysis 11.24.4. Business Strategy & Recent Development 11.25. Glaxosmithkline Plc (GSK) 11.25.1. Company overview 11.25.2. Financial performance 11.25.3. Product Portfolio Analysis 11.25.4. Business Strategy & Recent Development 11.26. Genelex 11.26.1. Company overview 11.26.2. Financial performance 11.26.3. Product Portfolio Analysis 11.26.4. Business Strategy & Recent Development 11.27. Johnson & Johnson 11.27.1. Company overview 11.27.2. Financial performance 11.27.3. Product Portfolio Analysis 11.27.4. Business Strategy & Recent Development 11.28. HealthCore, Inc. 11.28.1. Company overview 11.28.2. Financial performance 11.28.3. Product Portfolio Analysis 11.28.4. Business Strategy & Recent Development 11.29. Dako A/S 11.29.1. Company overview 11.29.2. Financial performance 11.29.3. Product Portfolio Analysis 11.29.4. Business Strategy & Recent Development List of Tables (92 Tables) TABLE 1. Market, Based on Technology, 2021-2030 (USD Million) TABLE 2. Market FOR Big Data Analytics, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Bioinformatics, BY REGION, 2021-2030 (USD Million) TABLE 4. Market FOR Gene Sequencing, BY REGION, 2021-2030 (USD Million) TABLE 5. Market FOR Drug Discovery, BY REGION, 2021-2030 (USD Million) TABLE 6. Market FOR Companion Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 7. Market FOR Other Technologies, BY REGION, 2021-2030 (USD Million) TABLE 8. Market, Based on Application, 2021-2030 (USD Million) TABLE 9. Market FOR Oncology, BY REGION, 2021-2030 (USD Million) TABLE 10. Market FOR Immunology, BY REGION, 2021-2030 (USD Million) TABLE 11. Market FOR Respiratory, BY REGION, 2021-2030 (USD Million) TABLE 12. Market FOR Other Applications, BY REGION, 2021-2030 (USD Million) TABLE 13. Market, BASED ON END-USER, 2021-2030 (USD Million) TABLE 14. Market FOR Healthcare Providers, BY REGION, 2021-2030 (USD Million) TABLE 15. Market FOR Pharmaceutical and Biotechnology Companies, BY REGION, 2021-2030 (USD Million) TABLE 16. Market FOR Research Centers and Academic Institutes, BY REGION, 2021-2030 (USD Million) TABLE 17. Market FOR Other End Users (non-profit organizations), BY REGION, 2021-2030 (USD Million) TABLE 18. Market, BY REGION, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA Market, Based on Technology, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA Market, Based on Application, 2021-2030 (USD Million) TABLE 22. NORTH AMERICA Market, BASED ON END-USER, 2021-2030 (USD Million) TABLE 23. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. EUROPE Market, Based on Technology, 2021-2030 (USD Million) TABLE 25. EUROPE Market, Based on Application, 2021-2030 (USD Million) TABLE 26. EUROPE Market, BASED ON END-USER, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC Market, Based on Technology, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC Market, Based on Application, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC Market, BASED ON END-USER, 2021-2030 (USD Million) TABLE 31. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 32. LAMEA Market, Based on Technology, 2021-2030 (USD Million) TABLE 33. LAMEA Market, Based on Application, 2021-2030 (USD Million) TABLE 34. LAMEA Market, BASED ON END-USER, 2021-2030 (USD Million) TABLE 35. SYAPSE, INC..: COMPANY SNAPSHOT TABLE 36. SYAPSE, INC..: OPERATING SEGMENTS TABLE 37. 2bPrecise LLC: COMPANY SNAPSHOT TABLE 38. 2bPrecise LLC: OPERATING SEGMENTS TABLE 39. Gene42, Inc.: COMPANY SNAPSHOT TABLE 40. Gene42, Inc.: OPERATING SEGMENTS TABLE 41. Foundation Medicine, Inc.: COMPANY SNAPSHOT TABLE 42. Foundation Medicine, Inc.: OPERATING SEGMENTS TABLE 43. FABRIC GENOMICS: COMPANY SNAPSHOT TABLE 44. FABRIC GENOMICS: OPERATING SEGMENTS TABLE 45. SOPHiA GENETICS SA: COMPANY SNAPSHOT TABLE 46. SOPHiA GENETICS SA: OPERATING SEGMENTS TABLE 47. PIERIANDX, INC.: COMPANY SNAPSHOT TABLE 48. PIERIANDX, INC.: OPERATING SEGMENTS TABLE 49. N-of-One, Inc.: COMPANY SNAPSHOT TABLE 50. N-of-One, Inc.: OPERATING SEGMENTS TABLE 51. Human Longevity, Inc..: COMPANY SNAPSHOT TABLE 52. Human Longevity, Inc..: OPERATING SEGMENTS TABLE 53. Sunquest Information: COMPANY SNAPSHOT TABLE 54. Sunquest Information: OPERATING SEGMENTS TABLE 55. Translational Software, Inc.: COMPANY SNAPSHOT TABLE 56. Translational Software, Inc.: OPERATING SEGMENTS TABLE 57. LLC: COMPANY SNAPSHOT TABLE 58. LLC: OPERATING SEGMENTS TABLE 59. NantHealth, Inc: COMPANY SNAPSHOT TABLE 60. NantHealth, Inc: OPERATING SEGMENTS TABLE 61. LifeOmic Health: COMPANY SNAPSHOT TABLE 62. LifeOmic Health: OPERATING SEGMENTS TABLE 63. Tempus Labs, Inc.: COMPANY SNAPSHOT TABLE 64. Tempus Labs, Inc.: OPERATING SEGMENTS TABLE 65. FLATIRON HEALTH, INC.: COMPANY SNAPSHOT TABLE 66. FLATIRON HEALTH, INC.: OPERATING SEGMENTS TABLE 67. IBM Watson Group.: COMPANY SNAPSHOT TABLE 68. IBM Watson Group.: OPERATING SEGMENTS TABLE 69. Koninklijke Philips N.V.: COMPANY SNAPSHOT TABLE 70. Koninklijke Philips N.V.: OPERATING SEGMENTS TABLE 71. Abbott: COMPANY SNAPSHOT TABLE 72. Abbott: OPERATING SEGMENTS TABLE 73. AB-Biotics SA: COMPANY SNAPSHOT TABLE 74. AB-Biotics SA: OPERATING SEGMENTS TABLE 75. GE Healthcare: COMPANY SNAPSHOT TABLE 76. GE Healthcare: OPERATING SEGMENTS TABLE 77. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT TABLE 78. LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS TABLE 79. Biocrates Life Sciences: COMPANY SNAPSHOT TABLE 80. Biocrates Life Sciences: OPERATING SEGMENTS TABLE 81. ABBOTT LABORATORIES: COMPANY SNAPSHOT TABLE 82. ABBOTT LABORATORIES: OPERATING SEGMENTS TABLE 83. Glaxosmithkline Plc (GSK): COMPANY SNAPSHOT TABLE 84. Glaxosmithkline Plc (GSK): OPERATING SEGMENTS TABLE 85. Genelex: COMPANY SNAPSHOT TABLE 86. Genelex: OPERATING SEGMENTS TABLE 87. Johnson & Johnson: COMPANY SNAPSHOT TABLE 88. Johnson & Johnson: OPERATING SEGMENTS TABLE 89. HealthCore, Inc.: COMPANY SNAPSHOT TABLE 90. HealthCore, Inc.: OPERATING SEGMENTS TABLE 91. Dako A/S: COMPANY SNAPSHOT TABLE 92. Dako A/S: OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Precision Medicine Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market Product-Based Estimation Figure 6 Top 29 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Cranial Implants, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Cranial Implants, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, Based on Technology, 2019 vs 2025 (USD Million) Figure 12 Market Share, Based on Application, 2019 vs 2025 (USD Million) Figure 13 Market Share, Based on End-User, 2019 vs 2025 (USD Million) Figure 14 Geographical Snapshot of the Market Figure 15 Drug discovery to Witness Higher CAGR in Market for Based on Technology Segment during Forecast Period. Figure 16 Oncology to Witness Higher CAGR in Market Based on Application Segment during Forecast Period. Figure 17 Pharmaceutical & Biotechnology Companies to Witness Higher CAGR in the Market Based on End-User Segment during Forecast Period. Figure 18 North America Region Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview